NK-cell therapy in resistant MDS, AML

Print Friendly, PDF & Email


Natural killer cell
destroying a cancer cell
Image by Joshua Stokes
Results of a phase 1/2 trial suggest treatment with haploidentical natural killer (NK) cells can be effective against relapsed/refractory myelodysplastic syndromes (MDS) and acute myeloid leukemia (AML). NK-cell therapy elicited responses in 6 of the 16 patients studied and provided a bridge... [Read Article]
Print Friendly, PDF & Email

Azacitidine now available in China

Print Friendly, PDF & Email


Vials of drug
Photo by Bill Branson
Azacitidine for injection (Vidaza®) is now available in China. The nucleoside metabolic inhibitor was approved in China to treat patients with intermediate-2/high-risk myelodysplastic syndromes (MDS), acute myeloid leukemia (AML) with 20% to 30% bone marrow blasts, and chronic myelomonocytic leukemia (CMML). Azacitidine for injection is marketed in... [Read Article]
Print Friendly, PDF & Email

Predicting response to AZA in MDS, CMML

Print Friendly, PDF & Email


Micrograph showing MDS
Researchers have developed a technique that may help predict whether patients with myelodysplastic syndromes (MDS) or chronic myelomonocytic leukemia (CMML) will respond to treatment with azacytidine (AZA). “The new method, called AZA-MS, utilizes a cutting-edge technique known as mass spectrometry to measure the different forms of AZA inside blood cells... [Read Article]
Print Friendly, PDF & Email

Rigosertib produces better OS in MDS than tAML

Print Friendly, PDF & Email


Micrograph showing
myelodysplastic syndrome
Rigosertib has demonstrated activity and tolerability in patients with myelodysplastic syndromes (MDS) and acute myeloid leukemia transformed from MDS (tAML), according to researchers. In a phase 1/2 study, rigosertib produced responses in a quarter of MDS/tAML patients and enabled stable disease in another quarter. Overall survival (OS) was about... [Read Article]
Print Friendly, PDF & Email

Generic azacitidine approved in Canada

Print Friendly, PDF & Email


Micrograph showing
acute myeloid leukemia
Health Canada has approved Dr. Reddy’s Laboratories Ltd.’s Azacitidine for Injection 100 mg/vial, a bioequivalent generic version of VIDAZA® (azacitidine for injection). The generic drug is approved for the same indications as VIDAZA®. This includes treating adults with intermediate-2 or high-risk myelodysplastic syndromes (according to the International... [Read Article]
Print Friendly, PDF & Email

ATLG fights GVHD but reduces PFS, OS

Print Friendly, PDF & Email


Micrograph showing GVHD
Image from PLOS ONE
Results of a phase 3 trial suggest rabbit anti-T lymphocyte globulin (ATLG) can reduce graft-versus-host disease (GVHD) but also decrease survival in patients who have received a hematopoietic stem cell transplant (HSCT) from a matched, unrelated donor. In this randomized trial, ATLG significantly decreased the incidence... [Read Article]
Print Friendly, PDF & Email

Mutations impact outcomes in AML, MDS

Print Friendly, PDF & Email


Azacitidine
Photo from Business Wire
Researchers say they have identified genetic mutations that can significantly affect treatment outcomes in patients with acute myeloid leukemia (AML) and myelodysplastic syndromes (MDS). The findings come from a clinical trial in which the team examined whether combining vorinostat with azacitidine could improve survival in patients with AML... [Read Article]
Print Friendly, PDF & Email